Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1L | First-line treatment |
| 2L+ | Second-line or later treatment |
| 5-D | Five-dimensional itch scale |
| AASLD | American Association for the Study of Liver Diseases |
| AHFS | American Hospital Formulary Service |
| AISF | Associazione Italiana per lo Studio del Fegato |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| AMA | Antimitochondrial antibody |
| ASP | Average sales price |
| AUC | Area under the concentration-time curve |
| CAS | Chemical Abstracts Service |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| DDI | Drug-drug interaction |
| EASL | European Association for the Study of the Liver |
| EC50 | Half-maximal effective concentration |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| GGT | Gamma-glutamyl transferase |
| HI | Hepatic impairment |
| hPPAR | Human peroxisome proliferator-activated receptor |
| IBAT | Ileal bile acid transporter |
| IP | Inpatient |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MSP | Moderate-to-severe pruritus |
| NDA | New Drug Application |
| NHS | National Health System |
| NMA | Network meta-analysis |
| NMP | No or mild pruritus |
| NRS | Numerical rating scale |
| OCA | Obeticholic acid |
| PBC | Primary biliary cholangitis |
| PBC-40 | 40-item primary biliary cholangitis questionnaire |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PPAR | Peroxisome proliferator-activated receptor |
| QALY | Quality-adjusted life-year |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| UDCA | Ursodeoxycholic acid |
| ULN | Upper limit of normal |
| WAC | Wholesale acquisition cost |